A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)

Trial Profile

A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Ubenimex (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Proof of concept; Therapeutic Use
  • Acronyms LIBERTY
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 29 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.
    • 09 Nov 2017 According to Eiger BioPharmaceuticals media release, dosing has been completed in this study.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top